<DOC>
	<DOC>NCT00610714</DOC>
	<brief_summary>The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer</brief_summary>
	<brief_title>AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Have a diagnosis of advanced ovarian cancer Have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy Estimated life expectancy of more than 12 weeks Central Nervous System (CNS) metastases Received more than 2 prior chemotherapy regimens for ovarian cancer treatment Inadequate bone marrow reserve Inadequate liver function, renal function or low haemoglobin Pregnant, breastfeeding or if of childbearing status unwilling to use an acceptable method of contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Ovarian Cancer</keyword>
</DOC>